Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency.

@article{Daniell2006OpenlabelPS,
  title={Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency.},
  author={Harry W. Daniell and Robin Lentz and Norman A. Mazer},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2006},
  volume={7 3},
  pages={200-10}
}
UNLABELLED We conducted a 24-week open-label pilot study of testosterone (T) patch therapy in 23 men with opioid-induced androgen deficiency (OPIAD). The T dosage was 5 mg/day for the first 12 weeks and 7.5 mg/day for the second 12 weeks. Seven subjects discontinued prematurely: 4 for noncompliance, 2 for skin irritation and 1 for hepatitis C treatment. In the "completers" population (n = 16), mean (SD) free T levels (normal range 52 to 280 pg/mL) were 28.5 (18.6) pg/mL at baseline, 72.8 (29.6… CONTINUE READING